title: In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer.
abstract: OBJECTIVE
  The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer.
  
  
  METHODS
  A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index.
  
  
  RESULTS
  The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin.
  
  
  CONCLUSIONS
  ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.
authors.affiliation: Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Seulkee
authors.initials: S
authors.lastname: Park
authors.forename: Yanghee
authors.initials: Y
authors.lastname: Woo
authors.forename: Hogeun
authors.initials: H
authors.lastname: Kim
authors.forename: Yong Chan
authors.initials: YC
authors.lastname: Lee
authors.forename: Sungho
authors.initials: S
authors.lastname: Choi
authors.forename: Woo Jin
authors.initials: WJ
authors.lastname: Hyung
authors.forename: Sung Hoon
authors.initials: SH
authors.lastname: Noh
references.citation: Onkologie. 2003 Dec;26 Suppl 7:54-9
references.pmid: 14716144
references.citation: Hematol Oncol. 1985 Jan-Mar;3(1):1-10
references.pmid: 2580768
references.citation: Gynecol Oncol. 2000 May;77(2):258-63
references.pmid: 10785475
references.citation: Ann Surg Oncol. 1995 Nov;2(6):488-94
references.pmid: 8591078
references.citation: Br J Cancer. 2001 Apr 6;84(7):878-80
references.pmid: 11286464
references.citation: Yonsei Med J. 2009 Oct 31;50(5):697-703
references.pmid: 19881975
references.citation: Cancer Res. 1983 Apr;43(4):1926-31
references.pmid: 6339044
references.citation: Cancer Treat Rep. 1986 Nov;70(11):1283-95
references.pmid: 2429763
references.citation: Cancer. 1991 Jan 1;67(1):20-7
references.pmid: 1985717
references.citation: J Clin Oncol. 2004 Sep 1;22(17):3631-8
references.pmid: 15289488
references.citation: Anticancer Drugs. 1996 Aug;7(6):630-5
references.pmid: 8913430
references.citation: N Engl J Med. 2001 Sep 6;345(10):725-30
references.pmid: 11547741
references.citation: Recent Results Cancer Res. 1984;94:1-7
references.pmid: 6494573
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: Anticancer Res. 2005 Sep-Oct;25(5):3453-9
references.pmid: 16101163
references.citation: Cancer Res. 1987 Feb 15;47(4):936-42
references.pmid: 3802100
references.citation: Melanoma Res. 2001 Dec;11(6):601-9
references.pmid: 11725206
references.citation: N Engl J Med. 2007 Nov 1;357(18):1810-20
references.pmid: 17978289
references.citation: Cancer Treat Rev. 1984 Mar;11 Suppl A:113-24
references.pmid: 6428738
references.citation: Proc Natl Acad Sci U S A. 1987 Jul;84(14):5029-33
references.pmid: 3474637
references.citation: Br J Surg. 2000 Feb;87(2):236-42
references.pmid: 10671934
references.citation: Ann Oncol. 2008 Apr;19(4):631-40
references.pmid: 18281267
references.citation: Proc Natl Acad Sci U S A. 1986 Apr;83(8):2694-8
references.pmid: 3458228
references.citation: Cancer Res Treat. 2005 Aug;37(4):223-7
references.pmid: 19956518
references.citation: Cancer Res. 1982 Jun;42(6):2159-64
references.pmid: 7074595
references.citation: Int J Clin Oncol. 2006 Dec;11(6):449-53
references.pmid: 17180513
references.citation: Breast Cancer Res Treat. 1999 Jan;53(1):77-85
references.pmid: 10206075
references.citation: Oncology. 2007;73(5-6):439-40
references.pmid: 18523363